Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.55 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | MDM4 | O15151 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29792372 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL178744 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL29374829 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL30649315 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL29352017 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL29768913 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL29792120 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL120511 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| Water SCHEMBL22070159 | 0.99 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| Water SCHEMBL31472478 | 0.99 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117886748-A | Quinoline amino acid conjugate and preparation method and application thereof | 天津科技大学 | 2024-04-16 | — | — | CN | claimed |
| CN-116178214-B | Preparation method of N- (9-fluorenylmethoxycarbonyl) -glutamic acid-1-tert-butyl ester | 吉尔生化（上海）有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-117510377-A | Synthesis method of N alpha-fluorenylmethoxycarbonyl-glutamic acid-alpha-tert-butyl ester | 常州吉恩药业有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-116178214-A | Preparation method of N- (9-fluorenylmethoxycarbonyl) -glutamic acid-1-tert-butyl ester | 吉尔生化（上海）有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-103342737-A | Caspase 3-sensitive fluorescence enhancement nano developer and preparation method thereof | USTC UNIV SCIENCE TECH CN | 2013-10-09 | — | — | CN | claimed |
| US-20030155554-A1 | PLASTICIZED, ANTIPLASTICIZED AND CRYSTALLINE CONDUCTING POLYMERS AND PRECURSORS THEREOF | GLOBALFOUNDRIES U.S. INC. | 2003-08-21 | — | — | US | claimed |
| US-12551582-B2 | Granzyme B directed imaging and therapy | CYTOSITE BIOPHARMA INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260007758-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) NON-PEPTIDE DRUG CONJUGATES AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250262312-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC (US) | 2025-08-21 | — | — | US | disclosed |
| WO-2025131978-A1 | DRUG-LINKER REAGENTS FOR CONJUGATION | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | WO | disclosed |
| US-20250195683-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEROF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-19 | — | — | US | disclosed |
| EP-4548937-A1 | ANTIBODY-DRUG COMPLEX | Eisai R&D Management Co., Ltd. (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-20250108123-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| US-5917034-A | Antithrombotic n-amidinopiperidine and benzamidine derivatives | PFIZER INC. (US) | 1999-06-29 | — | — | US | disclosed |
| EP-0922710-A1 | PEPTIDES PROMOTING THE ACTIVATION OF LATENT TGF-$g(b) AND METHOD FOR SCREENING TGF-$g(b) ACTIVITY REGULATORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-06-16 | — | — | EP | disclosed |
| EP-0858458-A1 | ANTITHROMBOTIC N-AMIDINOPIPERIDINE AND BENZAMIDINE DERIVATIVES | Pfizer Limited (GB) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997016444-A1 | ANTITHROMBOTIC N-AMIDINOPIPERIDINE AND BENZAMIDINE DERIVATIVES | PFIZER LIMITED (GB) | 1997-05-09 | — | — | WO | disclosed |
| EP-0770623-A1 | NOVEL CALCITONIN DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| US-5506267-A | IMMUNOADJUVANT FOR BONE MARROW CELL GROWTH AFTERTREATMENT OF CHEMOTHERAPY OR RADIOTHERAPY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-09 | — | — | US | disclosed |
| EP-0641776-A2 | Thioglycerol derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195683-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEROF | CD47, ABCB1, EGFR | MDM2 2059/4885TLR2 2732/4885MDM4 3536/4885 |
| US-20250262312-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | MDM2 993/4885TLR2 2459/4885MDM4 1741/4885 |
| US-20250108123-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | STING1, IRF3, CGAS | MDM2 4499/4885TLR2 53/4885MDM4 4471/4885 |
| US-20260007758-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) NON-PEPTIDE DRUG CONJUGATES AND USES THEREOF | SSTR4, SSTR1, SSTR3 | MDM2 4546/4885TLR2 973/4885MDM4 4679/4885 |
| US-12551582-B2 | Granzyme B directed imaging and therapy | GZMB, PRF1, CTSB | MDM2 4848/4885TLR2 4366/4885MDM4 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.